Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389792 | 1.00 | TGFBR1 (0.39) | TGFBR1MAPK14MEN1KMT2AGBA1 | |
| SCHEMBL29796672 | 0.87 | TGFBR1 (0.38) | TGFBR1 | |
| SCHEMBL23389877 | 0.87 | TGFBR1 (0.38) | TGFBR1 | |
| SCHEMBL23408101 | 0.77 | TGFBR1 (0.39) | TGFBR1MAPK14 | |
| SCHEMBL23389936 | 0.77 | CCR1 (0.40) | TGFBR1MAPK14 | |
| SCHEMBL29796504 | 0.77 | CCR1 (0.40) | TGFBR1MAPK14 | |
| SCHEMBL29796551 | 0.76 | TGFBR1 (0.37) | TGFBR1MAPK14GBA1RAB9AGRM5 | |
| SCHEMBL23389751 | 0.76 | TGFBR1 (0.37) | TGFBR1MAPK14GBA1RAB9AGRM5 | |
| SCHEMBL3813984 | 0.75 | EGFR (0.41) | KMT2A | |
| SCHEMBL5232777 | 0.74 | TGFBR1 (0.46) | TGFBR1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061809-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |